Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 414 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Load more HOT NEWS How My Metastatic Cancer Diagnosis Led Me to a Full-Time Career... FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib...
